Ports may offer easier way to deliver prostate cancer drug

NCT ID NCT06858995

Completed Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether Pluvicto, a radioactive drug for prostate cancer, can be safely given through a permanently implanted port (TIVAP) instead of a standard IV. Researchers measured if any drug got stuck in the port in 107 patients. The goal was to see if using the port is a practical option for patients with difficult veins.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pluvicto (177Lu-PSMA-617)
What this could lead to: If successful, this could show that using an existing port (TIVAP) is a safe and effective way to give Pluvicto, making treatment easier for patients with poor vein access.
What could go wrong: This is a small, completed observational study, not a large trial. It only checks if the drug sticks to the port, not whether it improves treatment outcomes or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADMINISTRATION OF THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADMINISTRATION OF THERAPY

Contacts and locations

Locations

CHRU de NANCY

Vandœuvre-lès-Nancy, 54511, France
Nuclear medicine Department CHRU de NANCY

Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.